Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation

Steve N. Caritis, Shringi Sharma, Raman Venkataramanan, Gary D. Hankins, Menachem Miodovnik, Mary F. Hebert, Jason G. Umans, Thomas Benedetti, Donald Mattison, Anne Zajicek, Dawn Fischer, Aimee Jackson

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Objective: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation. Study Design: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery. Results: The half-life (median ± SD) of 17-OHPC was 16.2 ± 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection. Conclusion: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier.

Original languageEnglish (US)
Pages (from-to)398.e1-398.e8
JournalAmerican journal of obstetrics and gynecology
Issue number5
StatePublished - Nov 2012
Externally publishedYes


  • cord blood
  • pharmacokinetics
  • placenta
  • preterm birth

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation'. Together they form a unique fingerprint.

Cite this